Published in Mol Neurodegener on August 20, 2012
Recent advances in quantitative neuroproteomics. Methods (2013) 1.23
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLoS One (2015) 0.84
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci (2014) 0.80
Mass spectrometry quantification of PICALM and AP180 in human frontal cortex and neural retina. Anal Biochem (2013) 0.77
Mass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns. Proteomics Clin Appl (2015) 0.76
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A (2003) 10.82
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. Nat Methods (2005) 2.81
Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol Cell Proteomics (2007) 2.63
Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron (1990) 2.09
Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem (2003) 2.01
Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics. Mol Cell Proteomics (2007) 1.26
An initial characterization of the serum phosphoproteome. J Proteome Res (2009) 1.26
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int (2006) 1.24
Optimizing the conditions of a multiple reaction monitoring assay for membrane proteins: quantification of cytochrome P450 11A1 and adrenodoxin reductase in bovine adrenal cortex and retina. Anal Chem (2010) 1.23
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem (1996) 1.15
Strategy combining separation of isotope-labeled unfolded proteins and matrix-assisted laser desorption/ionization mass spectrometry analysis enables quantification of a wide range of serum proteins. Anal Biochem (2008) 1.11
Stoichiometry and absolute quantification of proteins with mass spectrometry using fluorescent and isotope-labeled concatenated peptide standards. Mol Cell Proteomics (2007) 1.08
A synthetic protein approach toward accurate mass spectrometric quantification of component stoichiometry of multiprotein complexes. J Proteome Res (2007) 0.95
Clusterin mRNA and protein in Alzheimer's disease. J Alzheimers Dis (2012) 0.87
Quantotypic properties of QconCAT peptides targeting bovine host response to Streptococcus uberis. J Proteome Res (2012) 0.87
Optimizing the conditions of a multiple reaction monitoring assay for membrane proteins: quantification of cytochrome P450 11A1 and adrenodoxin reductase in bovine adrenal cortex and retina. Anal Chem (2010) 1.23
Natural flanking sequences for peptides included in a quantification concatamer internal standard. Anal Chem (2014) 1.14
Strategy combining separation of isotope-labeled unfolded proteins and matrix-assisted laser desorption/ionization mass spectrometry analysis enables quantification of a wide range of serum proteins. Anal Biochem (2008) 1.11
Sample prefractionation for mass spectrometry quantification of low-abundance membrane proteins. Anal Chem (2012) 0.99
Quantification of cholesterol-metabolizing P450s CYP27A1 and CYP46A1 in neural tissues reveals a lack of enzyme-product correlations in human retina but not human brain. J Proteome Res (2010) 0.98
Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase. Arch Biochem Biophys (2009) 0.97
Porous-wall hollow glass microspheres as novel potential nanocarriers for biomedical applications. Nanomedicine (2009) 0.89
Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells. J Lipid Res (2011) 0.89
15N-labeled full-length apolipoprotein E4 as an internal standard for mass spectrometry quantification of apolipoprotein E isoforms. Anal Chem (2012) 0.88
Isolevuglandins and mitochondrial enzymes in the retina: mass spectrometry detection of post-translational modification of sterol-metabolizing CYP27A1. J Biol Chem (2011) 0.86
Proteomic technologies for the discovery of type 1 diabetes biomarkers. J Diabetes Sci Technol (2010) 0.86
Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification. Rapid Commun Mass Spectrom (2011) 0.86
Studies of membrane topology of mitochondrial cholesterol hydroxylases CYPs 27A1 and 11A1. Lipids (2008) 0.85
Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. J Biol Chem (2014) 0.84
Quantification of amyloid precursor protein isoforms using quantification concatamer internal standard. Anal Chem (2012) 0.82
Mass spectrometry assessment of ubiquitin carboxyl-terminal hydrolase L1 partitioning between soluble and particulate brain homogenate fractions. Anal Chem (2013) 0.82
Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light. J Biol Chem (2013) 0.82
Quantifying the cluster of differentiation 4 receptor density on human T lymphocytes using multiple reaction monitoring mass spectrometry. Anal Chem (2013) 0.81
Features of the retinal environment which affect the activities and product profile of cholesterol-metabolizing cytochromes P450 CYP27A1 and CYP11A1. Arch Biochem Biophys (2011) 0.81
Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry. Biochemistry (2009) 0.80
Expression and characterization of 15N-labeled human C-reactive protein in Escherichia coli and Pichia pastoris for use in isotope-dilution mass spectrometry. Protein Expr Purif (2012) 0.80
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. PLoS One (2013) 0.79
Mass spectrometry quantification revealed accumulation of C-terminal fragment of apolipoprotein E in the Alzheimer's frontal cortex. PLoS One (2013) 0.77
Accumulation of large protein fragments in prematurely senescent ARPE-19 cells. Invest Ophthalmol Vis Sci (2009) 0.77
Mass spectrometry quantification of PICALM and AP180 in human frontal cortex and neural retina. Anal Biochem (2013) 0.77
Determining carbapenemase activity with 18O labeling and targeted mass spectrometry. Anal Chem (2013) 0.77
Quantification of transferrin in human serum using both QconCAT and synthetic internal standards. Anal Chem (2013) 0.76